SAB Biotherapeutics, Inc. (SABS) Revenue History
Annual and quarterly revenue from 2019 to present
SABS Revenue Over Time (2019–2025)
SABS Revenue Growth History
2 of 6 years with positive growth- FY2019 revenue growth
- N/A
- FY2020 revenue growth
- +1504.8%
- FY2021 revenue growth
- +10.2%
- FY2022 revenue growth
- -60.7%
- FY2023 revenue growth
- -90.6%
- FY2024 revenue growth
- -40.9%
- FY2025 revenue growth
- -100.0%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $0 | — |
| Q4 2025 | $0 | -100.0% |
| Q3 2025 | $0 | — |
| Q2 2025 | $0 | -100.0% |
| Q1 2025 | $0 | -100.0% |
| Q4 2024 | $115K | -62.4% |
| Q3 2024 | $0 | -100.0% |
| Q2 2024 | $263K | +207.7% |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2022)
SABS's revenue distribution by segment and geography for fiscal year 2022
By Product/Segment
SABS Revenue Analysis (2019–2025)
Current Revenue & Growth
As of June 22, 2026, SAB Biotherapeutics, Inc. (SABS) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q1 2026) recorded $0 in revenue
Historical Growth Trajectory
SABS's historical revenue data shows various trends over time. SAB Biotherapeutics, Inc.'s highest annual revenue of $60.9 million was recorded in 2021.
Revenue by Segment
SABS's revenue is primarily driven by Grant (100%). With over half of revenue concentrated in Grant, the company has a focused business model while developing other growth vectors.
Peer Comparison
Compared to Healthcare sector peers — including ARGX (+174.0% YoY), HALO (+39.1% YoY), and ADMA (+11.0% YoY). Compare SABS vs ARGX →
SABS Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| SABSCurrent | $0 | - | - | - | |
 ARGX | $4.2B | +174.0% | +151.5% | 25.4% | |
 HALO | $1.4B | +39.1% | +39.2% | 58.4% | |
 ADMA | $510M | +11.0% | +64.6% | 37.5% |
SABS Historical Revenue Data (2019–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | -100.0% | $-3,081,586 | - | $-48,953,363 | - |
| 2024 | $1.3M | -40.9% | $-3,470,185 | -262.4% | $-42,910,520 | -3244.9% |
| 2023 | $2.2M | -90.6% | $-1,506,000 | -67.3% | $-38,075,000 | -1700.5% |
| 2022 | $23.9M | -60.7% | $20.6M | 86.2% | $-28,918,000 | -121.0% |
| 2021 | $60.9M | +10.2% | $59.2M | 97.3% | $-13,393,000 | -22.0% |
| 2020 | $55.2M | +1504.8% | $55.2M | 100.0% | $20.6M | 37.2% |
| 2019 | $3.4M | - | $3.4M | 100.0% | $-8,674,000 | -252.0% |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
7+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
SABS — Frequently Asked Questions
Quick answers to the most common questions about buying SABS stock.
Is SABS's revenue growth accelerating or slowing?
SABS TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is SABS's revenue history from 2019 to 2026?
SAB Biotherapeutics, Inc. (SABS) revenue history spans 2019 to 2026. TTM revenue as of 2026 is $0.00, growing at N/A YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is SABS's long-term revenue growth rate (CAGR)?
SAB Biotherapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of N/A is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for SABS.
Why does SABS's quarterly revenue fluctuate?
SABS quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. SAB Biotherapeutics, Inc.'s revenue data from 2019 to 2026 shows full historical quarterly detail on this page.
How is SABS's revenue distributed by segment?
SABS reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does SABS's revenue compare to industry peers?
SAB Biotherapeutics, Inc. (SABS) with TTM revenue of $0.00 and N/A YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.